2 weeks Ago By Defense World Staff
Wells Fargo & Company MN boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 63,237 shares of the specialty pharmaceutical company’s stock after buying an additional 7,961 shares during the quarter. Wells Fargo & Company MN owned approximately 0.11% of Supernus Pharmaceuticals worth $2,287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. Exchange Traded Concepts LLC grew its stake in Supernus Pharmaceuticals by 2.6% during the fourth quarter.
Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 7.3% in the fourth quarter.
HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after buying an additional 624 shares in the last quarter. Bridge City Capital LLC boosted its stake in Supernus Pharmaceuticals by 0.8% during the fourth quarter.
Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company’s stock valued at $3,435,000 after buying an additional 761 shares during the period. Rhumbline Advisers grew its position in Supernus Pharmaceuticals by 0.5% during the fourth quarter.
Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after buying an additional 800 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Supernus Pharmaceuticals by 0.7% in the 4th quarter.
Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company’s stock valued at $3,920,000 after acquiring an additional 800 shares in the last quarter. Supernus Pharmaceuticals Trading Up 2.8 %Shares of Supernus Pharmaceuticals stock opened at $32.
22 on Friday. The firm has a market capitalization of $1.80 billion, a PE ratio of 30.
11 and a beta of 0.90. Supernus Pharmaceuticals, Inc.
has a 12 month low of $25.53 and a 12 month high of $40.28.
The business’s 50-day moving average price is $31.94 and its 200-day moving average price is $34.97.
Insiders Place Their BetsIn other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.
05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95.
This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Also, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.
62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.
38. This represents a 6.45 % decrease in their position.
The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 over the last quarter. 9.
30% of the stock is owned by corporate insiders. Analyst Upgrades and DowngradesSUPN has been the topic of several research analyst reports. StockNews.
com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th. Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
Check Out Our Latest Stock Report on SUPNAbout Supernus Pharmaceuticals (Free Report)Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.Featured ArticlesFive stocks we like better than Supernus PharmaceuticalsHow to Invest in the FAANG StocksShort Sellers Gave Up on These 3 Names RecentlyUsing the MarketBeat Stock Split Calculator3 Boring Stocks Outperforming the Market This YearStock Market Upgrades: What Are They?If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyWant to see what other hedge funds are holding SUPN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report)..
